Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia
Manfredi, R.; Sabbatani, S.
Hepato-Gastroenterology 54(78): 4PagePreceedingTableContent
2007
ISSN/ISBN: 0172-6390 PMID: 18019674 Document Number: 610732
Document emailed within 1 workday
Related Documents
Marcos Sánchez, F.; Juárez Ucelay, F.; Plaza Díaz, R.; Durán Pérez-Navarro, A. 1995: Filgrastim in the treatment of severe neutropenia in a patient with bilobar pneumonia Anales de Medicina Interna 12(2): 100-101Mira, J.é A.; López-Cortés, L.F.; Merino, D.; Arizcorreta-Yarza, A.; Rivero, A.; Collado, A.; Ríos-Villegas, M.ía.J.; González-Serrano, M.; Torres-Tortoso, M.; Macías, J.; Valera-Bestard, B.ár.; Fernández-Fuertes, E.; Girón-González, J.é A.; Lozano, F.; Pineda, J.A. 2007: Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients Antiviral Therapy 12(8): 1225-1235
Ersbøll, J. 1991: Filgrastim--a hematopoietic growth factor (r-metHuC-CSF) for treatment of neutropenia caused by cytostatics Ugeskrift for Laeger 153(38): 2647-2650
Sood, A.; Midha, V.; Sood, N.; Bansal, M. 2006: Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 25(6): 283-285
Čalkić, L.; Bajramović-Omeragić, L.; Husić-Selimović, A.; Aličković, I. 2017: Hbsag Seroconversion in the Treatment of Chronic Hepatitis B with Pegylated Interferon Lijecnicki Vjesnik 139(1-2): 29-32
Shi, Y.-k.; He, X.-h.; Yang, S.; Wang, H.-q.; Jiang, Z.-f.; Zhu, Y.-z.; Ke, X.-y.; Zhang, Y.; Liu, Y.-p.; Zhang, W.-j.; Wang, Z.; Shi, Q.-z.; Xie, X.-d.; Zhang, H.-l.; Wang, J.-j.; Luo, D.-y.; Zheng, Q.-s.; Sun, R.-y. 2006: Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase Ii clinical study Zhonghua Yi Xue Za Zhi 86(48): 3414-3419
Pawłowska, M.łg.; Halota, W. 2006: Pegylated interferon alpha in the treatment of chronic hepatitis B in HBe negative patients Przeglad Epidemiologiczny 60(1): 105-108
Urbánek, P.; Subhanová, I.; Janousová, E.; Dusek, L.; Marecek, Z.; Brůha, R.; Petrtýl, J.; Brodanová, M. 2009: Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV Vnitrni Lekarstvi 55(5): 474-479
Sarin, S.K.; Kumar, M.; Hissar, S.; Sharma, B.C. 2006: Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment Hepatobiliary and Pancreatic Diseases International: Hbpd Int 5(3): 374-380
Ali, S.; Nazir, G.; Khan, S.A.; Iram, S.; Fatima, F. 2010: Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients Journal of Ayub Medical College Abbottabad: Jamc 22(4): 127-130
Vogel, M.; Nattermann, J.; Baumgarten, A.; Klausen, G.; Bieniek, B.; Schewe, K.; Jessen, H.; Boesecke, C.; Rausch, M.; Lutz, T.; Fenske, S.; Schranzo, D.; Kümmerle, T.; Schuler, C.; Theisen, A.; Mayr, C.; Seidel, T.; Rockstroh, J.ür.K. 2006: Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals Antiviral Therapy 11(8): 1097-1101
Langer, C.; Lengfelder, E.; Thiele, Jürgen.; Kvasnicka, H.M.; Pahl, H.L.; Beneke, H.; Schauer, S.; Gisslinger, H.; Griesshammer, M. 2005: Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study Haematologica 90(10): 1333-1338
Słuzewski, W.; Kowala-Piaskowska, A.; Wysocki, J.; Figlerowicz, M.; Gorczyca, A.; Halota, W.; Jóźwiak, H.; Mizerski, J.; Mozer-Lisewska, I.; Pawłowska, M.łg.; Rokitka, M.; Strawińska, E.; Szamotulska, K. 2012: Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin--a multi-center study Acta Poloniae Pharmaceutica 69(2): 319-326
Abutidze, A.; Bolokadze, N.; Chkhartishvili, N.; Sharvadze, L.; Tsertsvadze, T. 2016: Incidence of Tuberculosis among Hiv/Hcv Co-Infected Patients Receiving Hepatitis C Treatment with Pegylated Interferon and Ribavirin in Georgia Georgian Medical News 252: 10-15
Husa, P.; Husova, L. 2001: Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons Bratislavske Lekarske Listy 102(5): 248-252
Durand-Gasselin, B.; Lortholary, O.; Tod, M.; Guillevin, L.; Casassus, P. 1997: Efficacy of teicoplanin in Staphylococcus aureus catheter-related tricuspid endocarditis during severe neutropenia Annales de Medecine Interne 148(7): 502-503
Vashakidze, E.; Imnadze, T. 2017: Combined Antiviral Treatment of Hepatitis C Virus Infection with Pegylated Interferon (Peg-Ifn) Α-2a (Pegferon) and Ribavirin (Copegus) in Inmates Georgian Medical News 264: 86-90
Chu, C-Jen.; Wang, Y-Jen.; Hwang, S-Jang.; Lu, R-Hwa.; Chang, F-Young.; Chang, C-Yu.; Yang, Y-Chun.; Lee, S-Dong. 2007: Kinetics of hepatitis C virus RNA load during pegylated interferon plus ribavirin therapy in Treatment-naive Chinese patients Hepato-Gastroenterology 54(75): 866-870
Mozer-Lisewska, I.; Dworacki, G.; Kaczmarek, E.; Słuzewski, W.; Kowala-Piaskowska, A.; Figlerowicz, M.; Kaczmarek, M.; Zeromski, J. 2005: Alterations within white blood cell subsets in children with chronic viral hepatitis C before treatment with pegylated interferon and ribavirin Przeglad Epidemiologiczny 59(2): 483-489
Elefsiniotis, I.S.; Fotos, N.V.; Pantazis, K.D.; Papadeli, D.; Mavrogiannis, C. 2007: Celiac disease in chronic hepatitis C patients under pegylated-interferon plus ribavirin treatment. Preliminary results of a prospective single center study Hepato-Gastroenterology 54(75): 2 PPreceding Table of Contents